These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention. Kupisiewicz K Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989 [TBL] [Abstract][Full Text] [Related]
4. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925 [TBL] [Abstract][Full Text] [Related]
5. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors. Zannettino AC; Farrugia AN; To LB; Atkins GJ Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108 [TBL] [Abstract][Full Text] [Related]
6. beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Tucci M; De Palma R; Lombardi L; Rodolico G; Berrino L; Dammacco F; Silvestris F Cancer Res; 2009 Aug; 69(16):6738-46. PubMed ID: 19654300 [TBL] [Abstract][Full Text] [Related]
7. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700 [TBL] [Abstract][Full Text] [Related]
8. Role of osteoblast suppression in multiple myeloma. Stewart JP; Shaughnessy JD J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324 [TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365 [TBL] [Abstract][Full Text] [Related]
15. [Bone disease in multiple myeloma and its mechanism]. Abe M Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506 [TBL] [Abstract][Full Text] [Related]
16. Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells. Tucci M; Stucci S; Felici C; Cafforio P; Resta L; Rossi R; Silvestris F Br J Haematol; 2016 Apr; 173(1):59-69. PubMed ID: 26728969 [TBL] [Abstract][Full Text] [Related]
17. Controlled environment culture of bone marrow explants from human myeloma. Gailani S; McLimans WF; Mundy GR; Nussbaum A; Roholt O; Zeigel R Cancer Res; 1976 Apr; 36(4):1299-304. PubMed ID: 4220 [TBL] [Abstract][Full Text] [Related]
18. Osteoblast function in myeloma. Roodman GD Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285 [TBL] [Abstract][Full Text] [Related]
19. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486 [TBL] [Abstract][Full Text] [Related]
20. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]